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clear segregation. Overall treatment results were similar to
delayed treatment ones. CONCLUSION: No statistic differences
were found between treatments in acute effectiveness, and hence
cost minimization analysis was only considered. GR showed to
be more cost-effective than ON in delayed and overall emesis
treatment.
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OBJECTIVES: The purpose of this study was to evaluate the
cost-effectiveness of capecitabine (Xeloda®) for the treatment
of advanced gastric cancer (aGC). This followed EMEA
approval in March 2007 and was intended initially to inform
an appraisal by the Scottish Medicines Consortium (SMC).
METHODS: Based on clinical effectiveness evidence demon-
strating that oral capecitabine is at least as good as IV 5-FU, a
cost-minimisation analysis was performed. The replacement of
continuous infusion IV 5-FU within a standard chemotherapy
regimen including cisplatin and epirubicin (ECF) by oral
capecitabine (ECX) was assessed. This analysis investigated the
comparative drug acquisition costs of ECX versus ECF regi-
mens, plus the incremental drug administration costs associated
with providing continuous infusion IV 5-FU. The administra-
tion costs included hospital visits, transport, staff time and dis-
posables. This health care resource utilisation (HCRU) was
associated with insertion and management of central venous
access lines, drug preparation, and use of infusional drug
pumps. HCRU and unit costing evidence sources included clini-
cal trials, published literature and an expert panel of specialists
(oncology doctors, nurses and pharmacists) with experience of
aGC management. Extensive sensitivity analysis assessed areas
of potential uncertainty. The primary perspective was from the
NHS, but a societal analysis was also undertaken. RESULTS:
Additional drug acquisition costs of 634 per patient course
for capecitabine are offset by drug administration savings of
1773. The net cost saving is 1139 per patient. Sensitivity
analysis demonstrates that capecitabine remains cost saving
across a range of uncertain parameters and under a number of
realistic scenarios. Also, oral dosing confers signiﬁcant beneﬁts
to patients in terms of personal time and cost savings. CON-
CLUSION: Capecitabine is cost saving in aGC and clearly
offers good value-for-money for both the NHS and patients.
Oral administration of chemotherapy in this therapy area may
also help address capacity limitations within the cancer service.
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OBJECTIVES: Trastuzumab (T) was recently approved to treat
women with HER2+ early breast cancer (eBC) following earlier
approval for metastatic breast cancer (mBC). The objective is to
estimate the potential aggregate economic value and the incre-
mental cost-utility ratio (ICUR) over T’s life cycle in ﬁve major
European countries from 2000 to 2020. METHODS: The pro-
jected life cycle ICUR was estimated by combining the ICURs of
T in eBC and mBC in a dynamic life cycle (DLM) model. The
model also projects the economic value to society, deﬁned as
monetized cumulative net quality-adjusted life years (QALYs)
gained minus net life-cycle treatment costs. Using indication-
speciﬁc ICURs (€43,000 per QALY in mBC and €15,000 per
QALY in eBC) and epidemiological projections of disease inci-
dence in Germany, France, UK, Italy, and Spain, the projected life
cycle ICUR and cumulative economic value were estimated, dis-
counting at 3.5%. RESULTS: We project a relative increase in the
number of women with HER2+ eBC vs. HER2+ mBC—a ratio of
3.4 in 2020 up from 2.1 in 2000. Over this period, the projected
overall mean ICUR was €18,000 per QALY with a total of
800,000 discounted QALYs gained. Scenario analysis was per-
formed for alternative use rates and ICURs. When benchmarked
against potentially acceptable values per QALY of €50,000 or
€100,000, the total projected economic value of T treatment
would range from €30 to €70 billion, respectively. CONCLU-
SION: Application of a DLM estimation approach to the case of
trastuzumab demonstrates that: 1) the economic value of a
product can change due to life-cycle innovation, and 2) typical
static, indication-speciﬁc cost-effectiveness models do not
account for the interdependence of drug development and
adoption decisions over the life cycle. This raises important
policy questions about the appropriate perspective—static vs.
dynamic—and reimbursement for an innovative product whose
economic value changes over time.
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OBJECTIVES: The objective of this economic evaluation was to
estimate the cost-effectiveness of HuIFN-á as adjuvant treatment
for patients with resected cutaneous malignant melanoma in
stage IIb-III in a Swedish setting. METHODS: The economic
evaluation is based on a prospective multicentre study, in which
252 patients with totally resected cutaneous melanoma in stage
II-IV (whereof 158 high-risk patients with melanoma in stage
IIb-III) were randomised to induction treatment with dacarba-
zine (DTIC) followed by six months adjuvant treatment with
low-dose natural human interferon alpha (HuIFN-á) versus no
adjuvant treatment. A Markov model was developed to assess
the costs and clinical outcomes of DTIC/HuIFN-á compared
with no adjuvant treatment. Time-to-progression and overall
survival were based on data from the clinical study. The model
compares two groups of patients, 54 years old at base-line, and
adopts a life-long horizon. The primary clinical outcome measure
is quality-adjusted life years (QALYs) gained. Direct medical
costs were included in the analysis. An additional analysis was
performed that included costs of added years of life for the
Swedish population. Cost and outcome data were discounted
with a 3% annual rate. Sensitivity analyses were performed to
test the stability of the base case results. RESULTS: The eco-
nomic analysis showed that adjuvant treatment with HuIFN-á
for stage IIb-III melanoma patients resulted in €8200 higher costs
and 2.5 additional QALYs, leading to an incremental cost per
QALY gained of €3300 compared to no adjuvant treatment.
Including costs of added years of life increased the cost per QALY
gained to about €21,100. The results were stable in sensitivity
analyses. CONCLUSION: The economic evaluation indicates
that adjuvant treatment with HuIFN-á is cost-effective for
patients with resected cutaneous malignant melanoma in stage
IIb-III.
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